Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:GLSI

Greenwich LifeSciences 5/20/2025 Earnings Report

Greenwich LifeSciences logo
$27.65 +0.46 (+1.69%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$27.55 -0.10 (-0.36%)
As of 05/22/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Greenwich LifeSciences EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.24
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Greenwich LifeSciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Greenwich LifeSciences Announcement Details

Quarter
Date
5/20/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Greenwich LifeSciences' next earnings date is estimated for Tuesday, May 26, 2026, based on past reporting schedules.

Conference Call Resources

Greenwich LifeSciences Earnings Headlines

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
May 22 at 4:30 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/22/3300368/0/en/greenwich-lifesciences-announces-receipt-of-nasdaq-notice-regarding-late-form-10-q-filing.html
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
April 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284599/0/en/greenwich-lifesciences-provides-update-regarding-form-10-k-filing.html
Elon Musk’s $1 Quadrillion AI IPO
$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.tc pixel
May 23 at 1:00 AM  |  Brownstone Research (Ad)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), Greenwich LifeSciences (GLSI) and Harmony Biosciences Holdings (HRMY)
April 23, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/HRMY/pressreleases/1454109/analysts-opinions-are-mixed-on-these-healthcare-stocks-hims-hers-health-hims-greenwich-lifesciences-glsi-and-harmony-biosciences-holdings-hrmy/
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026
April 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/23/3279668/0/en/greenwich-lifesciences-announces-acceptance-of-abstract-at-asco-2026.html
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
April 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/22/3279449/0/en/greenwich-lifesciences-announces-receipt-of-nasdaq-notice-regarding-late-form-10-k-filing.html
See More Greenwich LifeSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Greenwich LifeSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Greenwich LifeSciences and other key companies, straight to your email.

About Greenwich LifeSciences

Greenwich LifeSciences (NASDAQ:GLSI) (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States. The company leverages proprietary technologies to identify immune-modulating compounds and works with contract research organizations to support its preclinical and clinical programs.

Greenwich LifeSciences pursues strategic collaborations and licensing arrangements to expand its scientific expertise and accelerate the progress of its therapeutic candidates. With a focus on unmet medical needs in oncology and inflammatory disorders, the company aims to bring first-in-class or best-in-class treatments to patients through disciplined clinical development and regulatory strategies.

View Greenwich LifeSciences Profile
Earnings Tools